Cargando…
Benefits from the first year of GnRHa therapy in boys with idiopathic central precocious puberty when initiating treatment after age 9 years: findings from a real-world retrospective study
BACKGROUND: GnRHa treatment was established for improving final adult height (FAH) in children presenting with Idiopathic central precocious puberty (ICPP) up to age 8, while several controversies remained for older age groups. The primary objective was to evaluate whether boys diagnosed with ICPP o...
Autores principales: | Ni, Ming-ming, Yang, Shu-ting, Wu, Wen-wen, Wang, Shan-shan, Li, Man, Liu, Qing-qing, Ji, Xing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716691/ https://www.ncbi.nlm.nih.gov/pubmed/36456936 http://dx.doi.org/10.1186/s12902-022-01207-z |
Ejemplares similares
-
Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty
por: Lewis, Katherine A, et al.
Publicado: (2009) -
A single sample GnRHa stimulation test in the diagnosis of precocious puberty
por: Yazdani, Parvin, et al.
Publicado: (2012) -
Treatment of central precocious puberty using low dose GnRH analogs (GnRHa)
por: Jahagirdar, Rahul, et al.
Publicado: (2015) -
GnRHa/Stanozolol Combined Therapy Maintains Normal Bone Growth in Central Precocious Puberty
por: Zhu, Shunye, et al.
Publicado: (2021) -
The Efficacy of GnRHa Alone or in Combination with rhGH for the Treatment of Chinese Children with Central Precocious Puberty
por: Wang, Mengjie, et al.
Publicado: (2016)